Related Experiment Video
Updated: Sep 7, 2025

Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
Softer More Frequent Stools in Infants With Difficult Stooling Fed Hydrolyzed Protein Formula With Added Prebiotics:
Veronica Fabrizio1,2, Cheryl L Harris1, Kelly R Walsh1
1Medical and Scientific Affairs, Reckitt | Mead Johnson Nutrition Institute (MJNI), Evansville, IN, United States.
Insights
A new partially hydrolyzed protein infant formula with prebiotics effectively softened stools and increased frequency in infants experiencing constipation. This formula was well-tolerated and showed no significant differences in adverse events compared to standard formula.
Area of Science:
- Pediatrics
- Gastroenterology
- Nutrition Science
Background:
- Infant constipation is a common concern, impacting infant well-being and parental stress.
- Standard infant formulas may contribute to hard stools, necessitating specialized formulations.
- Prebiotics are known to influence gut microbiota and stool consistency.
Purpose of the Study:
- To evaluate the efficacy of a partially hydrolyzed protein (PHF) infant formula with added prebiotics in softening stools.
- To assess stool frequency and other infant outcomes in a randomized controlled trial.
Main Methods:
- A multi-center, double-blind, controlled study randomized infants (28-300 days) to PHF or intact protein formula for 14 days.
- Both formulas contained a prebiotic blend (polydextrose and galactooligosaccharides).
- Parent-reported stool consistency (1=hard, 5=watery) and frequency were primary outcomes.
Main Results:
- Infants fed PHF formula had significantly softer stools (3.4 vs 3.0, P=0.019) and higher stool frequency (1.5 vs 1.0, P=0.002) compared to controls at study end.
- Stool consistency improved within the first 3 days of feeding in both groups.
- Crying, fussing, and pain during stooling decreased from baseline in both groups.
Conclusions:
- A partially hydrolyzed protein infant formula with prebiotics is well-tolerated.
- This specialized formula effectively softens stools and increases stool frequency in infants with constipation.
- The formula offers a beneficial option for managing infant constipation and improving comfort.
Objective:
To evaluate stool consistency in infants with reported hard or infrequent stools fed hydrolyzed protein formula with added prebiotics designed to promote stool softening.
Methods:
In this multi-center, double-blind, controlled study, eligible infants (28-300 days of age at enrollment) were randomized to: partially hydrolyzed cow's milk protein formula (PHF, 75% carbohydrate as lactose; 12 mg Mg/100 kcal; n = 49) or routine intact protein cow's milk-based infant formula (Control, 92% carbohydrate as lactose; 8 mg Mg/100 kcal; n = 51) over a 14-day period. Both formulas had a prebiotic blend (polydextrose and galactooligosaccharides, 4 g/L; 1:1 ratio). Parent-reported stool consistency (hard = 1 through watery = 5) and other daily outcomes were collected by diary. Endpoint stool consistency (mean score over last 3 days of study feeding) was the primary outcome. Adverse events were recorded.
Results:
Baseline stool consistency (Control: 1.4 ± 0.1, PHF: 1.4 ± 0.1) and frequency were similar between groups; the majority had hard (n = 61, 64%) or formed (n = 30, 32%) stools. Stool consistency became softer over Day 1-3 (Control: 2.5 ± 0.1, PHF: 2.6 ± 0.1) and remained similar from Day 4 to 6 through study end (post hoc analysis). For PHF vs Control, endpoint stool consistency was significantly softer (3.4 ± 0.1 vs 3.0 ± 0.1; P = 0.019) and frequency significantly higher (1.5 ± 0.1 vs 1.0 ± 0.1; P = 0.002). Crying, fussing, and appearance of pain during stooling decreased from baseline to study end in both groups. Formula intake, infant fussiness and incidence of adverse events were similar between groups.
Conclusion:
An infant formula designed to promote stool softening was well-tolerated and associated with softer, more frequent stools in infants with reported hard or infrequent stools.
More Related Videos
09:36Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers
Published on: July 28, 2022
07:11Assessment of the Efficacy of An Osteopathic Treatment in Infants with Biomechanical Impairments to Suckling
Published on: February 5, 2019
Related Concept Videos
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs Affecting GI Tract Motility: Other Laxatives
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are: